Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2024 | $4.00 | Buy | Maxim Group |
| 5/6/2024 | $6.00 | Perform → Outperform | Oppenheimer |
| 12/19/2023 | $7.00 | Buy | ROTH MKM |
| 3/10/2022 | $30.00 → $20.00 | Outperform | Oppenheimer |
| 12/7/2021 | $30.00 | Buy | Aegis Capital |
4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corpor
TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development. "We believe Dr. Frankel's wealth of experience across all aspects of clinical development and medical affairs, along with his outstanding performance in helping to bring biologic and
─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. "Ch
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key biomarkers of liver injury, inflammation and fibrosis, including ELF score, fibrosis-related ELF score components and PRO-C3 Patients treated with nebokitug for 48 weeks showed a significantly lower number of clinical events compared to matching historical controls and significantly reduced progression of liver stiffness vs historical controls, further derisking the planned PSC Phase 3 clinical trial design
Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc).1 The data will be presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025) on March 8, 2025, in Venice, Italy. Systemic sclerosis is an auto
─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with No Liver Biopsies or Confirmatory Studies Needed; Nebokitug Positioned to Potentially Become the First FDA-Approved Treatment for PSC─ ─On Track for Releasing Clinical Data from SPRING Trial Open Label Extension in First Quarter 2025─ ─Discussions with Potential Strategic Partners Ongoing─ TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), a clinical stage biotechnology compan
TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.
TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company
First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f
Maxim Group initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $4.00
Oppenheimer upgraded Chemomab Therapeutics from Perform to Outperform and set a new price target of $6.00
ROTH MKM resumed coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $7.00
SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)
SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)
SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)